会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • NOVEL PROCESS FOR PRODUCTION OF CABERGOLINE
    • 生产咖啡因的新工艺
    • WO2005085243A2
    • 2005-09-15
    • PCT/HU2005000022
    • 2005-03-02
    • RICHTER GEDEON VEGYESZETGALAMBOS JANOSCZIBULA LASZLOSEBOK FERENCBALINT SANDORNEKASSAI FERENCNEIGNACZNE SZENDREI GYOERGYIDEMETER ADAM
    • GALAMBOS JANOSCZIBULA LASZLOSEBOK FERENCBALINT SANDORNEKASSAI FERENCNEIGNACZNE SZENDREI GYOERGYIDEMETER ADAM
    • C07D457/06C07D457/00
    • C07D457/06
    • A process for preparing cabergoline (I) from ergoline-8beta-carboxylic acid ester (XIII) comprising the following steps. (a) reacting an ergoline-8beta-carboxylic acid ester of formula (XIII), wherein R1 represents a C1-4 alkyl group, in the presence of a catalyst (i) with a compound of formula (XIV), X-COOR2 (XIV) wherein R2 is an optionally substituted straight or branched C1-6 alkyl group, X represents a bromine or chlorine atom, or (ii) with a compound of formula (XV), O(COOR2)2 (XV) wherein R2 is a group as defined above; (b) reacting the obtained carbamate derivative of formula (XVI) with 3-(dimethylamino)-propylamine (DMAPA) in the presence of a catalyst; (c) reacting the obtained ergoline-8beta-carboxamide derivative of formula (XVII) with ethyl isocyanate (EtNCO) in the presence of ligand(s) and Ib and IIb metal group salt catalysts; (d) reacting the obtained protected N-acylurea derivative of formula (XVIII) with a strong aqueous inorganic acid (aq./acid); (e) reacting the obtained secondary amine (XIX) with an electrophyl allyl alcohol derivative in the presence of a palladium or nickel containing catalyst and optionally in the presence of ligand(s) to form cabergoline (I). The intermediates of (XVI), (XVII), (XVIII) and (XIX) are novel. The polymorphic amorphous form of Cabergoline (I) and the production thereof.
    • 一种从麦角灵八羧酸酯(XIII)制备卡麦角林(I)的方法,包括以下步骤。 (ⅰ)在催化剂(ⅰ)与式(ⅩⅣ)的化合物,X-COOR2(ⅩⅣ)的存在下,使式(ⅩⅩⅢ)的麦角灵-8-羧酸酯,其中R 1表示C 1-4烷基, XIV)其中R2是任选取代的直链或支链C 1-6烷基,X代表溴或氯原子,或(ii)与式(ⅩⅤ)化合物,O(COOR 2)2(ⅩⅤ)化合物,其中R 2是 组如上所述; (b)在催化剂存在下使所得得到的式(ⅩⅥ)的氨基甲酸酯衍生物与3-(二甲氨基) - 丙胺(DMAPA)反应; (c)在配体和Ib和IIb金属盐盐催化剂存在下,使得到的式(XVII)的麦角灵八乙酰胺衍生物与异氰酸乙酯(EtNCO)反应; (d)使得到的式(XVIII)的保护的N-酰基脲衍生物与强无机酸水溶液(水溶液)反应; (e)在含钯或镍的催化剂存在下,任选地在配体存在下,使得到的仲胺(XIX)与电子烯丙基醇衍生物反应形成卡麦角林(I)。 (XVI),(XVII),(XVIII)和(XIX)的中间体是新的。 卡麦角林(I)的多晶型无定形形式及其生产。
    • 4. 发明申请
    • PROCESS FOR THE SYNTHESIS OF N- [3-(3-CYANOPYRAZOLO [1,5A] PYRIMIDIN-7-YL)-PHENYL]-N-ETHYL-ACETAMIDE
    • 合成N- [3-(3-氰基吡唑并[1,5-a]嘧啶-7-基) - 苯基] -N-乙基 - 乙酰胺的方法
    • WO2005073235A3
    • 2005-10-06
    • PCT/HU2005000008
    • 2005-01-31
    • RICHTER GEDEON VEGYESZETCZIBULA LASZLODOBAY LASZLOSZOKE KATALINWERKNE PAPP EVANAGYNE BAGDY JUDITTARKANYI GABOR
    • CZIBULA LASZLODOBAY LASZLOSZOKE KATALINWERKNE PAPP EVANAGYNE BAGDY JUDITTARKANYI GABOR
    • C07D487/04
    • C07D487/04C07C233/43
    • The invention relates to N- [3- (3-cyanopyrazolo [1,5-a] pyrimidin-7-yl) - phenyl]-N-ethyl-acetamide of formula (IV) containing less than 0.2 % impurities, which is suitable for therapeutic application. Furthermore the invention relates to a process for the synthesis of therapeutically applicable compound of formula (IV) containing less than 0.2 % impurities by reacting the new intermediate N-{3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl}-N-ethyl­acetamide hydrochloride of formula (II) and 3-amino-4-pyrazol-carbonitrile base of formula (III) in an acid free medium. The invention also relates to the new N- {3- [3- (dimethylamino) -1- oxo -2- ­propenyl]phenyl } -N-ethyl-acetamide hydrochloride of formula (II). The invention also relates to a process for the synthesis of the new N- [3- [3, (dimethylamino)-1-oxo-2-propenyl]phenyl}-N-ethyl-acetamide hydrochloride of formula (II) having a purity of more than 99.5 %. Furthermore the invention relates to N-{3-[3-cyanopyrazolo (1,5-a) pyrimidin]­6 -yl-3- [ (3-N-ethyl-acetamido-phenyl) -3-oxo-propen-1-yl] - (pyrimidin-7-yl) -phenyl} - N-ethyl-acet-amide of formula (V), which is an isolated new impurity formed in 0.07 % yield during the synthesis of compound of formula (IV).
    • 本发明涉及含有少于0.2%杂质的式(IV)的N- [3-(3-氰基吡唑并[1,5-a]嘧啶-7-基) - 苯基] -N-乙基 - 乙酰胺, 用于治疗应用。 此外,本发明涉及一种通过使新的中间体N- {3- [3-(二甲基氨基)-1-氧代-2-丙烯基] -1,3,5-三嗪与式(IV)化合物反应合成含有少于0.2% 苯基} -N-乙基乙酰胺盐酸盐和式(III)的3-氨基-4-吡唑甲腈碱在无酸介质中反应。 本发明还涉及式(II)的新的N- {3- [3-(二甲基氨基)-1-氧代-2-丙烯基]苯基} -N-乙基 - 乙酰胺盐酸盐。 本发明还涉及合成式(II)的新的N- [3- [3(二甲基氨基)-1-氧代-2-丙烯基]苯基} -N-乙基 - 乙酰胺盐酸盐的方法, 超过99.5%。 此外,本发明涉及N- {3- [3-氰基吡唑并(1,5-a)嘧啶] -6-基-3 - [(3-N-乙基 - 乙酰氨基 - 苯基)-3-氧代 - 嘧啶-7-基] - 苯基} -N-乙基 - 乙酰胺,其是在合成式(IV)化合物期间以0.07%收率形成的分离的新杂质。
    • 10. 发明专利
    • PROCESO PARA PREPARAR FLUCONAZOL Y SUS MODIFICACIONES CRISTALINAS.
    • ES2252209T3
    • 2006-05-16
    • ES01921683
    • 2001-03-23
    • RICHTER GEDEON VEGYESZET
    • KREIDL JANOSCZIBULA LASZLOSZANTAY CSABAFARKAS JENONEDEUTSCHNE JUHASZ IDAHEGEDUS ISTVAN
    • C07D249/08
    • Nuevo proceso para la síntesis de monohidrato de fluconazol y de las modificaciones cristalinas de fluconazol, de fórmula (I) caracterizado porque a) se hidroliza un derivado silil éter de fórmula (II) donde R2 es hidrógeno o un grupo alquilo(C1-C10) o fenilo, R3 y R4, independientemente uno de otro, son un grupo alquilo(C1-C10) o fenilo, en solución acuosa, luego, se enfría la mezcla de reacción obtenida que contiene el fluconazol de fórmula (I) y se separa el monohidrato precipitado de fluconazol y opcionalmente se disuelve el monohidrato de fluconazol obtenido a partir de la hidrólisis de silil-fluconazol en un alcohol de 1 a 4 carbonos de cadena lineal o ramificada, a temperatura de ebullición, y se enfría la solución a una velocidad de 5-15ºC/hora para obtener la modificación cristalina II de fluconazol, o b) se disuelve el fluconazol anhidro o el monohidrato del mismo en un alcohol de 1 a 4 carbonos de cadena lineal o ramificada, a temperatura de ebullición y se enfría la solución a una velocidad de 5-15ºC/hora para obtener la modificación cristalina II de fluconazol, o c) secado lento del monohidrato de fluconazol a 30-70ºC, para obtener la modificación cristalina II de fluconazol, o d) secado rápido del monohidrato de fluconazol a 80ºC, para obtener la modificación cristalina I de fluconazol.